Results 61 to 70 of about 317,688 (249)

Prevención e identificación temprana de casos sospechosos COVID-19 en el primer nivel de atención en Centro América

Atención Primaria, 2021
Karla Iveth Henriquez-Marquez, Lysien I. Zambrano, Kovy Arteaga-Livias, Alfonso J. Rodríguez-Morales   +3 more
doaj   +1 more source

Duration and key determinants of infectious virus shedding in hospitalized patients with coronavirus disease-2019 (COVID-19) [PDF]

, 2021
Jeroen J. A. van Kampen, David van de Vijver, Pieter L. A. Fraaij, Bart L. Haagmans, Mart M. Lamers, Nisreen M.A. Okba, Johannes P. C. van den Akker, Henrik Endeman, Diederik Gommers, Jan J. Cornelissen, Rogier A.S. Hoek, Menno M. van der Eerden, Dennis A. Hesselink, Herold J. Metselaar, Annelies Verbon, Jurriaan E. M. de Steenwinkel, Georgina I. Aron, Eric C. M. Van Gorp, Sander van Boheemen, Jolanda J.C. Voermans, Charles A. Boucher, Richard Molenkamp, Marion Koopmans, Corine H. GeurtsvanKessel, Annemiek A. van der Eijk   +24 more
openalex   +1 more source

Harnessing chimeric antigen receptor macrophages against solid tumors

Cancer Communications, EarlyView.
Abstract Macrophages are prevalent in multiple tumors and exhibit diverse and potent functional activities. Therapeutic reprogramming of macrophage phenotypes represents a promising strategy for cancer immunotherapy. Engineering chimeric antigen receptors (CARs) to endow macrophages with anti‐tumor capacities demonstrated encouraging efficacy ...
Mengru Wang, Zhen Qin, Xiu‐Wu Bian, Yu Shi   +3 more
wiley   +1 more source

Evolving Real‐World Data and Evidence Use for New Drugs and Regenerative Medical Products Approvals in Japan—An Analysis of the 6‐Year Trend

Clinical Pharmacology &Therapeutics, EarlyView.
Several regulatory initiatives have been made to clarify the acceptability and requirements of real‐world data and real‐world evidence (RWD/E) for the benefit/risk assessment of new medical products in Japan. The objectives of this review were to characterize the use of RWD/E in regulatory applications of new medical products and to describe the ...
Suguru Okami, Kako Shimotsumagari, Yasunari Sadatsuki   +2 more
wiley   +1 more source

An Overview of COVID-19 Medicines in Current Guidelines

Bezmiâlem Science, 2020
An acute respiratory disease caused by a new coronavirus (Severe acute respirotary syndrome-coronavirüs-2, previously known as 2019-nCoV), coronavirus disease 2019 (COVID-19), appeared in December 2019 and then has spread rapidly throughout the world ...
Mustafa GÖKÇE, Eray Metin GÜLER
doaj   +1 more source

Recommendations for breastfeeding during Coronavirus Disease 2019 (COVID-19) pandemic [PDF]

, 2022
Xiyao Liu, Haoyue Chen, Meijing An, Wangxing Yang, Yujie Wen, Zhihuan Cai, Lulu Wang, Qianling Zhou   +7 more
openalex   +1 more source

Simultaneous vaccination against influenza and respiratory syncytial virus in high‐risk heart failure patients

ESC Heart Failure, EarlyView.
In a prospective, randomized study of high‐risk HF patients, simultaneous vaccination against influenza and RSV reduced the risk of the primary composite endpoint (hospitalization for HF, all‐cause death, or infection). The main driver of benefit was a lower incidence of infections.
Jan Biegus, Leszek Szenborn, Michał Tkaczyszyn, Robert Zymlinski, Gad Cotter, Michał Zakliczynski, Krzysztof Reczuch, Mateusz Guzik, Szymon Urban, Marta Rosiek‐Biegus, Berenika Jankowiak, Gracjan Iwanek, Marta Wleklik, Marat Fudim, Piotr Ponikowski   +14 more
wiley   +1 more source

One year after the arrival of COVID-19 in Latin America: what have we learned in Brazil and other countries?

Brazilian Journal of Infectious Diseases, 2021
Sergio Cimerman, Alberto Chebabo, Clovis Arns da Cunha, Alfonso J. Rodríguez-Morales   +3 more
doaj   +1 more source

Impact of standardized team‐based care on cardiogenic shock outcomes over time

ESC Heart Failure, EarlyView.
This contemporary North American cardiogenic shock (CS) registry aimed to investigate the influence of team‐based care on outcomes over a six‐year period of time following implementation of standardized protocols. Despite a two‐fold increase in the number of CS patients and changes in presentation and management strategies, no differences in in ...
Behnam N. Tehrani, Carolyn M. Rosner, Adetokunbo Fadahunsi, Kimberly Barker, Wayne B. Batchelor, Vanessa Blumer, Lindsay Clevenger, Shashank Desai, Michelle Ferri, Evan Franke, Jamie Kennedy, Christopher King, Edward Howard, Iyad Isseh, Seiyon Ben Lee, Aditya Mehta, Mitchell Psotka, Ramesh Singh, Shashank S. Sinha, Matthew W. Sherwood, Daniel Tang, Megan Terek, Alexander G. Truesdell, Ilan Vavilin, Christopher M. O'Connor   +24 more
wiley   +1 more source

Characteristics and outcomes of patients with heart failure and history of malignancy: Data from Swedish Heart Failure Registry and the National Cancer Register

European Journal of Heart Failure, EarlyView.
Prevalence and predictors of, and outcome associated with history of cancer in patients with heart failure. AF, atrial fibrillation; CI, confidence interval; COPD, chronic obstructive pulmonary disease; CV, cardiovascular; DM, diabetes mellitus; EF, ejection fraction; GDMT, guideline‐directed medical therapy; GI, gastrointestinal; Hb, haemoglobin; HF ...
Pietro Ameri, Paolo Costa, Lina Benson, Davide Stolfo, Nabil V. Sayour, Charlotta Ljungman, Javed Butler, Stefan D. Anker, Nicolas Girerd, Kalliopi Keramida, Gerasimos Filippatos, Lars H. Lund, Felix Lindberg, Gianluigi Savarese   +13 more
wiley   +1 more source